학술논문
Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma
Document Type
Article
Author
Leipold, Alexander M.; Werner, Rudolf A.; Düll, Johannes; Jung, Pius; John, Mara; Stanojkovska, Emilia; Zhou, Xiang; Hornburger, Hannah; Ruckdeschel, Anna; Dietrich, Oliver; Imdahl, Fabian; Krammer, Tobias; Knop, Stefan; Rosenwald, Andreas; Buck, Andreas; Sander, Leif Erik; Einsele, Hermann; Kortüm, K. Martin; Saliba, Antoine-Emmanuel; Rasche, Leo
Source
Leukemia; March 2023, Vol. 37 Issue: 3 p650-658, 9p
Subject
Language
ISSN
08876924; 14765551
Abstract
Pseudo-progression and flare-up phenomena constitute a novel diagnostic challenge in the follow-up of patients treated with immune-oncology drugs. We present a case study on pulmonary flare-up after Idecabtagen Vicleucel (Ide-cel), a BCMA targeting CAR T-cell therapy, and used single-cell RNA-seq (scRNA-seq) to identify a Th17.1 driven autoimmune mechanism as the biological underpinning of this phenomenon. By integrating datasets of various lung pathological conditions, we revealed transcriptomic similarities between post CAR T pulmonary lesions and sarcoidosis. Furthermore, we explored a noninvasive PET based diagnostic approach and showed that tracers binding to CXCR4 complement FDG PET imaging in this setting, allowing discrimination between immune-mediated changes and true relapse after CAR T-cell treatment. In conclusion, our study highlights a Th17.1 driven autoimmune phenomenon after CAR T, which may be misinterpreted as disease relapse, and that imaging with multiple PET tracers and scRNA-seq could help in this diagnostic dilemma.